Table 3.
Regression Analysis on T2D Risk Associated with CAPN10 Polymorphisms 1
| Univariate | Multivariate | ||||
|---|---|---|---|---|---|
| SNP | Genotype | P | OR (95% CI) | P | aOR 2 (95% CI) |
| UCSNP-43 | G/G | 0.647 | 1.00 (Reference) 3 | 0.809 | 1.00 (Reference) 3 |
| G/A | 0.573 | 1.52 (0.35 - 6.53) | 0.827 | 1.20 (0.24 - 6.12) | |
| A/A | 0.492 | 1.66 (0.39 - 7.03) | 0.708 | 1.36 (0.27 - 6.85) | |
| UCSNP-19 | 3R/3R | 0.003 | 1.00 (Reference) 3 | 0.084 | 1.00 (Reference) 3 |
| 3R/2R | 0.008 | 1.35 (1.08 - 1.68) | 0.923 | 1.02 (0.66 - 1.58) | |
| 2R/2R | 0.002 | 1.61 (1.20 - 2.18) | 0.044 | 1.40 (1.01 - 1.93) | |
| UCSNP-63 | C/C | 0.714 | 1.00 (Reference) 3 | 0.704 | 1.00 (Reference) 3 |
| C/T | 0.463 | 1.29 (0.66 - 2.52) | 0.722 | 1.19 (0.45 - 3.17) | |
| T/T | 0.417 | 1.31 (0.68 - 2.54) | 0.920 | 1.05 (0.39 - 2.85) | |
1. Study subjects comprised 917 cases and 748 age-, gender-, and origin-matched controls subjects.
2. aOR = adjusted OR; covariates included age, gender, BMI, hypertension, and lipid profile.
3. Reference group being minor allele non-carriers.